Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.3333.

Several research firms have commented on ENTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective for the company.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ENTA. Seven Fleet Capital Management LP acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $36,000. Virtu Financial LLC purchased a new stake in Enanta Pharmaceuticals during the fourth quarter worth approximately $220,000. Invesco Ltd. lifted its stake in Enanta Pharmaceuticals by 325.2% during the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock worth $4,003,000 after purchasing an additional 194,113 shares during the last quarter. Krensavage Asset Management LLC increased its stake in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after purchasing an additional 651,946 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $997,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $12.70 on Monday. The business’s 50-day moving average is $13.58 and its two-hundred day moving average is $12.34. The firm has a market capitalization of $368.55 million, a P/E ratio of -3.97 and a beta of 0.96. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The business had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%. On average, analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.